The role of Obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease
AbstractBackground. Obinutuzumab, a new-generation anti-CD20 monoclonal antibody, was originally emerged to overcome resistance to rituximab in B-cell mali